3,6-diaminopyrazine-2,5-dicarboxamide | 203798-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 3,6-diaminopyrazine-2,5-dicarboxamide
• 英文别名: 3,6-diamino-2,5-pyrazinedicarboxamide
• CAS: 203798-32-7
• 化学式: C₆H₈N₆O₂
• 分子量: 196.169
• InChiKey: YRYOEAFNIZMNRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  164
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  3,6-diaminopyrazine-2,5-dicarboxamide 在 水 、 potassium hydroxide 作用下， 生成 3,6-diaminopyrazine-2,5-dicarboxylic acid
  参考文献：
  名称：

  WO2022/212080

  摘要：

  公开号：
• 作为产物：
  描述：

  3,6-二氨基-2,5-吡嗪二甲腈 在 硫酸 、 水 作用下， 生成 3,6-diaminopyrazine-2,5-dicarboxamide
  参考文献：
  名称：

  WO2022/212080

  摘要：

  公开号：

文献信息

• ANODIC OXIDATION OF 5-AMINOURACIL
  申请人：MediBeacon Inc.

  公开号：US20210107881A1

  公开（公告）日：2021-04-15

  A process for preparing pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, or a salt thereof, is provided. A process for the preparation of 3,6-diaminopyrazine-2,5-dicarboxylic acid, or a salt thereof, from pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, or a salt thereof, is further provided. A process for preparing a substituted pteridine compound, or a salt thereof, is further provided. A process for the preparation of a N-substituted 3,6-diaminopyrazine-2,5-dicarboxylic acid from a substituted pteridine compound, or a salt thereof, is further provided.

  提供一种制备嘧啶并[4,5-g]喹啉-2,4,7,9-四醇或其盐的过程。进一步提供一种从嘧啶并[4,5-g]喹啉-2,4,7,9-四醇或其盐制备3,6-二氨基吡嗪-2,5-二羧酸或其盐的过程。进一步提供一种制备取代喹啉化合物或其盐的过程。进一步提供一种从取代喹啉化合物或其盐制备N-取代的3,6-二氨基吡嗪-2,5-二羧酸的过程。
• [EN] LUMINESCENT METAL COMPLEXES FOR MONITORING RENAL FUNCTION<br/>[FR] COMPLEXES MÉTALLIQUES LUMINESCENTS POUR LA SURVEILLANCE DES FONCTIONS RÉNALES
  申请人：MALLINCKRODT INC

  公开号：WO2006026038A1

  公开（公告）日：2006-03-09

  Some embodiments of the present invention may be said to be directed to metal complexes of Formula I, wherein at least one of X1, X2, X3, R1, R2, R3, R4 and R5 is what may be characterized as an antenna capable of providing (e.g., absorbing and/or emitting) an appropriate electromagnetic signal. Some embodiments of the present invention are directed to ligands corresponding to metal complexes of Formula I. Some embodiments of the invention are directed to methods of determining renal function using at least one metal complex of Formula I.

  本发明的某些实施例可被称为公式I的金属配合物，其中X1、X2、X3、R1、R2、R3、R4和R5中至少一个可被表征为天线，能够提供（例如吸收和/或发射）适当的电磁信号。本发明的某些实施例涉及与公式I的金属配合物相对应的配体。本发明的某些实施例涉及使用至少一个公式I的金属配合物来确定肾功能的方法。
• [EN] MODIFIED PYRAZINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS MODIFIÉS DE PYRAZINE ET LEURS UTILISATIONS
  申请人：MALLINCKRODT INC

  公开号：WO2010078025A1

  公开（公告）日：2010-07-08

  Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.

  本文提供了含有多个聚乙二醇取代基的吡嗪衍生物的化合物、制剂和配方。其中许多化合物可通过受试者或患者的肾系统排泄，并可用于可视化受试者或患者的肾系统。在电磁辐射的激发下，本文披露的一些化合物表现出发光性，并在患者或受试者的体液中存在时可外部检测到。本文还提供了可视化受试者或患者的肾系统的方法。
• Modified Pyrazine Derivatives and Uses Thereof
  申请人：Poreddy Amruta

  公开号：US20140186267A1

  公开（公告）日：2014-07-03

  Provided herein are compounds, preparations and formulations comprising pyrazine derivatives having multiple poly(ethylene glycol) containing substituents. Many of the compounds disclosed herein are excretable by the renal system of a subject or patient and are useful for visualizing the renal system of a subject or patient. Upon excitation by electromagnetic radiation, a number of the compounds disclosed herein exhibit luminescence and are externally detectable when present in the body fluid of a patient or subject. Also provided herein are methods for visualizing the renal system of a subject or patient.

  本文提供了含有多个聚乙二醇取代基的吡嗪衍生物的化合物、制剂和配方。本文披露的许多化合物可被患者的肾系统排泄，并可用于可视化患者的肾系统。在电磁辐射的激发下，本文披露的一些化合物表现出发光性，并在患者或受试者的体液中存在时可外部检测。本文还提供了可视化受试者或患者肾系统的方法。
• Hydrophilic Pyrazine Dyes as Exogenous Fluorescent Tracer Agents for Real-Time Point-of-Care Measurement of Glomerular Filtration Rate
  作者：Raghavan Rajagopalan、William L. Neumann、Amruta R. Poreddy、Richard M. Fitch、John N. Freskos、Bethel Asmelash、Kimberly R. Gaston、Karen P. Galen、Jeng-Jong Shieh、Richard B. Dorshow

  DOI：10.1021/jm200257k

  日期：2011.7.28

  Various hydrophilic pyrazine-bis(carboxamides) derived from 3,5-diamino-pyrazine-2,5-dicarboxylic acid bearing neutral and anionic groups were prepared and evaluated for use as fluorescent glomerular filtration rate (GFR) tracer agents. Among these, the dianionic D-serine pyrazine derivatives 2d and 2j, and the neutral dihydroxypropyl 2h, exhibited favorable physicochemical and clearance properties. In vitro studies show that 2d, 2h, and 2j have low plasma protein binding, a necessary condition for renal excretion. In vivo animal model results show that these three compounds exhibit a plasma clearance equivalent to iothalamate (a commonly considered gold standard GFR agent). In addition, these compounds have a higher urine recovery compared to iothalamate. Finally, the plasma clearance of 2d, 2h, and 2j remained unchanged upon blockage of the tubular secretion pathway with probenecid, a necessary condition for establishment of clearance via glomerular filtration only. Hence, 2d, 2h, and 2j are promising candidates for translation to the clinic as exogenous fluorescent tracer agents in real-time point-of-care monitoring of GFR.